Abstract 66P
Background
Glioblastoma is the most common primary malignancy of the brain, affecting approximately 3 per 100 000 people, with a median overall survival of 15 months. Tumor-associated macrophages comprise up to 30% of the glioblastoma tumor microenvironment (TME) and consist of microglia and monocyte-derived macrophages (MDM). MDM arise from granulocyte-monocyte progenitors (GMP) or monocyte-dendritic cell progenitors (MDP). Our recent work identified a unique macrophage population expressing myeloperoxidase (MPO) and other GMP-associated genes associated with long-term survival in glioblastoma patients. ScRNA-seq analysis suggests that MPO+ macrophages may arise from GMPs and are metabolically distinct from MPO- MDM. Interestingly, adoptive transfer of GMP- versus MDP-derived monocytes into glioma-bearing mice had opposing effects on tumor growth. GMP-lineages specifically delayed tumor growth—aligning with our correlative findings in patients. The role of metabolic changes on the anti-tumor function of MDM of distinct developmental lineages remains unknown. We hypothesize that metabolic differences between GMP- and MDP-derived MDM may shift nutrient partitioning within the TME.
Methods
Bulk RNA-seq of GMP- and MDP-MDM was performed. To functionally assess metabolic differences between GMP- and MDP-MDM, Seahorse XFe96 analysis as well as metabolite analysis of conditioned media will be performed.
Results
Bulk RNA-seq of GMP- and MDP-MDM showed differential expression of many metabolic pathways, notably, a downregulation of the pentose phosphate pathway and aerobic respiration in GMP-MDM compared to MDP-MDM. Furthermore, co-culturing GMP- or MDP-MDM with GL261 glioma cell line suggests GMP-MDM are more phagocytic towards tumor cells. We will perform Seahorse XFe96 analysis and metabolite analysis of the conditioned media from GMP-MDM vs. MDP-MDM to investigate the functional impact of metabolic differences further.
Conclusions
Understanding how metabolic differences of MDM derived from different lineages shift nutrient competition in the TME will lead to a better understanding of the roles of macrophages in the TME.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract